All Programs

Use the tool below to view all available Prova Series

Guideline Considerations for Immunotherapy in Primary Advanced or Recurrent Endometrial Cancer
Guideline Considerations for Immunotherapy in Primary Advanced or Recurrent Endometrial Cancer
MinuteCE®
Guideline Considerations for Immunotherapy in Primary Advanced or Recurrent Endometrial Cancer
1.00 program credit
- Susana Campos, MD, MPH
- Ritu Salani, MD, MBA
1.00 program credit
MinuteCE®
Innovations in Oncology Learning Center From Guidelines to Practice: Gynecologic Cancer
1.00 credit 10 episodes
- Susana Campos, MD, MPH
- Nicoletta Colombo, MD
- Ritu Salani, MD, MBA
1.00 credit 10 episodes
MinuteCE®
Innovations in Oncology Learning Center From Guidelines to Practice: Genitourinary Cancers
1.25 credits 10 episodes
- Ignacio Duran, MD
- Wenxin Xu, MD
- Sandy Srinivas, MD
1.25 credits 10 episodes
Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer
Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer
MinuteCE®
Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer
1.25 program credits
- Ignacio Duran, MD
- Wenxin Xu, MD
1.25 program credits
Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer
Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer
MinuteCE®
Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer
1.25 program credits
- Ignacio Duran, MD
- Sandy Srinivas, MD
1.25 program credits
Incorporation of guideline-concordant care for first-line treatment of a patient with metastatic urothelial carcinoma
Incorporation of guideline-concordant care for first-line treatment of a patient with metastatic urothelial carcinoma
MinuteCE®
Incorporation of guideline-concordant care for first-line treatment of a patient with metastatic urothelial carcinoma
1.25 program credits
- Ignacio Duran, MD
- Sandy Srinivas, MD
1.25 program credits
MinuteCE®
Advancing Prostate Cancer Care: Integrating Guideline Updates and Patient Preferences for Optimal ADT Management of Advanced Prostate Cancer
0.75 credits 7 episodes
- Tanya Dorff, MD
- Rana McKay, MD
0.75 credits 7 episodes
Guideline Recommendations for Biomarker-Directed Therapies in Cervical Cancer
Guideline Recommendations for Biomarker-Directed Therapies in Cervical Cancer
MinuteCE®
Guideline Recommendations for Biomarker-Directed Therapies in Cervical Cancer
1.00 program credit
- Ritu Salani, MD, MBA
- Nicoletta Colombo, MD
1.00 program credit
Testosterone Revisited: Importance of Monitoring and Impact of Rebound on Quality of Life in Advanced Prostate Cancer
Testosterone Revisited: Importance of Monitoring and Impact of Rebound on Quality of Life in Advanced Prostate Cancer
MinuteCE®
Testosterone Revisited: Importance of Monitoring and Impact of Rebound on Quality of Life in Advanced Prostate Cancer
0.75 program credits
- Tanya Dorff, MD
0.75 program credits
Implementing Guideline-Concordant Care Into the Management of Frontline Patients With Recurrent Endometrial Cancer
Implementing Guideline-Concordant Care Into the Management of Frontline Patients With Recurrent Endometrial Cancer
MinuteCE®
Implementing Guideline-Concordant Care Into the Management of Frontline Patients With Recurrent Endometrial Cancer
1.00 program credit
- Ritu Salani, MD, MBA
- Susana Campos, MD, MPH
1.00 program credit
Emerging immunotherapy combination strategies in genitourinary malignancies
Emerging immunotherapy combination strategies in genitourinary malignancies
MinuteCE®
Emerging immunotherapy combination strategies in genitourinary malignancies
1.25 program credits
- Sandy Srinivas, MD
1.25 program credits
Incorporation of guideline recommendations into the frontline care of a patient with mCRPC who is naïve to both docetaxel and novel hormone therapy
Incorporation of guideline recommendations into the frontline care of a patient with mCRPC who is naïve to both docetaxel and novel hormone therapy
MinuteCE®
Incorporation of guideline recommendations into the frontline care of a patient with mCRPC who is naïve to both docetaxel and novel hormone therapy
1.25 program credits
- Wenxin Xu, MD
- Sandy Srinivas, MD
1.25 program credits
Managing Adverse Effects of Oral vs Injectable ADT in Advanced Prostate Cancer
Managing Adverse Effects of Oral vs Injectable ADT in Advanced Prostate Cancer
MinuteCE®
Managing Adverse Effects of Oral vs Injectable ADT in Advanced Prostate Cancer
0.75 program credits
- Tanya Dorff, MD
0.75 program credits
Guideline Updates for ADT: Best Practices for Treating Advanced Prostate Cancer
Guideline Updates for ADT: Best Practices for Treating Advanced Prostate Cancer
MinuteCE®
Guideline Updates for ADT: Best Practices for Treating Advanced Prostate Cancer
0.75 program credits
- Tanya Dorff, MD
0.75 program credits
Agonists vs Antagonists: Evaluating ADT Efficacy as Monotherapy and Combination Therapy in Hormone-Sensitive Prostate Cancer
Agonists vs Antagonists: Evaluating ADT Efficacy as Monotherapy and Combination Therapy in Hormone-Sensitive Prostate Cancer
MinuteCE®
Agonists vs Antagonists: Evaluating ADT Efficacy as Monotherapy and Combination Therapy in Hormone-Sensitive Prostate Cancer
0.75 program credits
- Rana McKay, MD
0.75 program credits
Recent Advances in ADT: New Insights in Advanced Prostate Cancer Treatment
Recent Advances in ADT: New Insights in Advanced Prostate Cancer Treatment
MinuteCE®
Recent Advances in ADT: New Insights in Advanced Prostate Cancer Treatment
0.75 program credits
- Tanya Dorff, MD
- Rana McKay, MD
0.75 program credits

All Programs

Popular

Title

Share on ReachMD